Hologic loses patent suit to Smith & Nephew, has to pay $4M

Hologic's ($HOLX) two-year patent battle with Smith & Nephew ($SNN) over the patent to a surgical device has come to an end, and Hologic will have to fork over $4 million.

At issue is Hologic's MyoSure hysteroscopic tissue removal system--used to excise fibroids and polyps from the uterus--that the company absorbed in its $125 million buyout of Interlace Medical in 2011. S&N sued the two companies for patent infringement, and a Massachusetts jury this week ruled in the British orthopedic giant's favor, awarding S&N $4 million in damages for lost profits.

Under the terms of its Interlace acquisition, Hologic is indemnified only to a previously agreed upon dollar amount for any liabilities--like a lost lawsuit--but the company did not disclose how much of the $4 million will come from its coffers.

Hologic will keep MyoSure on the market, Senior Vice President Mark Casey said in a statement, and the company will consider an appeal. "This is but the first step in a multi-phase process, and there remain several issues to be decided by the Court which could impact the applicability of this verdict," Casey said.

- read Hologic's release
- get MassDevice's take

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.